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Editorial: surviving your genes—the role of PNPLA3 variation
in end‐stage liver disease
Nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease
(ALD) not only represent leading causes of chronic liver damage1,2
but share significant pathophysiological pathways of disease.3 Cur-
rent evidence suggests that NAFLD has ostensibly incremented not
only the burden of long‐term complications of end‐stage liver dam-
age, including cirrhosis and hepatocellular carcinoma, but also liver‐
and non‐liver‐related mortality.
While it is difficult to accurately predict which NAFLD patients
will clinically evolve more dramatically, it is clearly known that the
presence and severity of liver fibrosis4,5 are major determinants of the
natural history of the disease. Other concurrent factors that may
modify the clinical course of NAFLD predisposing to more aggressive
and severe damage include age, sex, ethnicity, comorbidities, and
genetic and epigenetic factors (Figure 1). The weight of each of these
factors in determining the risk of progression to cirrhosis and decom-
pensation in either NAFLD or ALD is only partially understood, partic-
ularly the size of the effect of the genetic influence.
In a recent issue of AP&T, Mandorfer and colleagues retrospec-
tively evaluated the impact of the missense PNPLA3‐rs738409 C>G
variant on liver‐related mortality in a cohort of patients with differ-
ent underlying diseases and portal hypertension at the time of diag-
nosis.6 The authors observed that homozygous status of the risk G‐
allele (rs738409‐GG) substantially increased mortality rates among
patients with NAFLD/ALD two‐fold without influencing survival rates
in patients with viral hepatitis. Altogether, these interesting results
require some reflection. First, mortality rates were significantly influ-
enced by PNPLA3 variant only in the recessive model of inheritance,
indicating that two copies of the G‐allele seem to be required for
increasing the risk of death. One might presume, however, that
owing to the small sample size of the included cohort, the effect of
the variant under the additive model, which is the model that has
been largely replicated as a modifier of the presence of NASH and
fibrosis,7 could not be properly assessed. Second, while the authors
have correctly adjusted their results by competing covariates, one
might still argue what the specific role of PNPLA3 variant is in deter-
mining mortality rates as the variant is undeniably a strong modifier
of the severity of liver steatosis and fibrosis ‐ the initial and final
outcomes, respectively (Figure 1). The lack of association between
the variant and a surrogate of steatosis may indicate the loss of a
substantial proportion of functional organ mass in these patients
with end‐stage hepatic disease. In this particular scenario, it is
difficult to explain the lack of effect of the PNPLA3 variant on mor-
tality due to viral hepatitis.
Finally, one might speculate that higher mortality rates in
NAFLD/ALD are indeed explained by yet unexplored gene‐by‐gene
interaction(s) with variant(s) located in gene(s) that may potentially
modify the course of cirrhosis and portal hypertension, then amplify-
ing the presence of deadly complications. For example, regulators of
hepatic and systemic vasomotor activity, hemodynamic circulation
and vascular remodelling, such as members of the angiotensin sys-
tem,8 might open further avenues for exploration novel gene‐gene
interaction networks and therapeutic options.
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F IGURE 1 The role of PNPLA3‐rs738409 in the Natural History of Progressive NASH. The figure depicts known risk factors involved in
modulating the aggressive course of NAFLD from NASH (nonalcoholic steatohepatitis)‐cirrhosis→hepatic decompensation, hepatocellular
carcinoma (HCC) to→ all causes of death. Genetic factors: PNPLA3 –missense rs738409 variant (I148M p.Ile148Met, based on the position
of the variant on the protein) modulates the susceptibility of NAFLD (5.3% of the total variance),7 the progression into NASH and the
severity of liver fibrosis (OR 1.88 per G allele),7 and potentially, the development of HCC.9 The variant also modulates other factors,
including sex (there is a negative correlation between male sex and the effect of the rs738409 on liver fat content7) and adiposity,10 and
presents large population diversity (from 12% in African population to 48% in South American and Mexican population) (http://browser.
1000genomes.org/Homo_sapiens/Variation/Population). The natural course of NAFLD, particularly the progression to severe histological
stages is modulated by other variants as well, including TM6SF2‐rs58542926 and the newly discovered insertion variant in HSD17B13
(rs72613567:TA),11 the later conferring protection from chronic liver damage. Nevertheless, is still uncertain the role of these two variants
in the development of HCC and decompensated liver disease. What is still poorly known is the burden of genetic influence in determining
mortality and survival from aggressive NASH. Fibrosis is a strong covariate that associates with both, the genetic predisposition (PNPLA3‐
rs738409) and the course of the disease. Therefore, fibrosis is a strong confounding factor as it seems to be the consequence of the
exposure as well. Hence, the association between the variant and the covariate‐fibrosis could bias the estimated effect of rs738409 on
hepatic decompensation and mortality in‐patients with NAFLD‐cirrhosis and portal hypertension. Information regarding gene‐gene interaction
and proper design in future studies, including longitudinal studies are essential to uncovering the role of genetic factors in survival and
mortality from NASH‐cirrhosis
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Editorial: surviving your genes—the role of PNPLA3 variation
in end‐stage liver disease. Authors’ reply
EDITORS,
We thank Drs. Pirola and Sookoian for reviewing the role of the
rs738409 C>G p.I148M variant in the patatin-like phospholipase
domain containing 3 (PNPLA3) gene and its interaction with other
genetic and nongenetic factors in modulating the course of (non‐
alcoholic) fatty liver disease as well as for their insightful comments
on our manuscript.1,2
Drs. Pirola and Sookoian argue that it remains unclear whether
the PNPLA3 G allele directly impacts liver‐related mortality, since
the G allele is linked to liver fibrosis, which drives the development
of complications in fatty liver disease. Importantly, patients were
characterised by hepatic venous pressure gradient (HVPG) measure-
ment, which shows a good correlation with quantitative measures
of liver fibrosis, such as collagen proportionate area (CPA).3 Both
HVPG and CPA allow for sub‐classification of advanced chronic liver
disease (ACLD; ie, advanced liver fibrosis/cirrhosis), and thus, have
important prognostic implications.4 However, in addition to the
structural component (eg, liver fibrosis), there is also a dynamic
component contributing to increased intrahepatic resistance,5 which
is particularly relevant in the presence of ongoing hepatic injury/in-
flammation6,7 and might also be affected by PNPLA3 genotype due
to its implications on hepatic stellate cell activation.8 Thus, HVPG,
as a function of both the structural and dynamic component of
intrahepatic resistance as well as the severity of splanchnic vasodi-
latation and hyperdynamic circulation,9 might even be a better indi-
cator of liver disease severity than liver fibrosis. For instance, in
non‐abstinent patients with alcoholic liver disease (ie, ongoing
hepatic injury/inflammation), HVPG predicted clinical outcomes,
while CPA (only indicative of the structural component, ie, liver
fibrosis) did not.10
Importantly, all patients included in our study had portal hyper-
tension, indicating ACLD.2 Moreover, we accounted for potential
differences in the severity of liver disease at baseline by adjusting
all our survival analyses for HVPG. Thus, the observed association
between PNPLA3 G/G genotype and hepatic decompensation/(liver‐
related) mortality in patients with fatty liver disease cannot be
explained by a more rapid progression to ACLD or more severe
liver fibrosis/portal hypertension at baseline. Interestingly, similar
observations were made in PNPLA3 G allele carriers with alcoholic
liver disease listed for liver transplantation,11 or survivors of an epi-
sode of severe alcoholic hepatitis harbouring the PNPLA3 G/G geno-
type.12 It is easily conceivable that harbouring the PNPLA3 G/G
genotype worsened prognosis in patients with fatty liver disease by
propagating the progression of liver fibrosis and portal hypertension
during follow‐up. Nevertheless, the exact pathophysiological mecha-
nisms, which seem to be unrelated to hepatic steatosis,2 as well as
the contribution of other unexplored factors (eg, gene‐gene interac-
tions, as suggested by Drs. Pirola and Sookoian), clearly warrant fur-
ther study.
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